| Dr Emily Ann Dimango, MD | |
|
622 W 168th St, New York, NY 10032-3720 | |
| (212) 305-0631 | |
| Not Available |
| Full Name | Dr Emily Ann Dimango |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 35 Years |
| Location | 622 W 168th St, New York, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407933195 | NPI | - | NPPES |
| 01441212 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 186447 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York-presbyterian Hospital | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trustees Of Columbia University In The City Of New York | 8527972546 | 1895 |
News Archive
University of Arizona Health Sciences researchers recently completed a study that has the potential to improve cancer treatment for colorectal cancer and melanoma by using nanotechnology to deliver chemotherapy in a way that makes it more effective against aggressive tumors.
A novel approach to treating children diagnosed with autism spectrum disorder could help them navigate their world by teaching them to turn their symptoms into strengths.
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that they received approval from the European Commission to proceed with Teva's acquisition of Barr.
The study evaluated the co-occurrence of cancers in patients with central nervous system disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorders, Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia.
Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids.
› Verified 5 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437176047 PECOS PAC ID: 6002715794 Enrollment ID: O20031231000637 |
News Archive
University of Arizona Health Sciences researchers recently completed a study that has the potential to improve cancer treatment for colorectal cancer and melanoma by using nanotechnology to deliver chemotherapy in a way that makes it more effective against aggressive tumors.
A novel approach to treating children diagnosed with autism spectrum disorder could help them navigate their world by teaching them to turn their symptoms into strengths.
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that they received approval from the European Commission to proceed with Teva's acquisition of Barr.
The study evaluated the co-occurrence of cancers in patients with central nervous system disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorders, Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia.
Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids.
› Verified 5 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982993184 PECOS PAC ID: 8527972546 Enrollment ID: O20040407001360 |
News Archive
University of Arizona Health Sciences researchers recently completed a study that has the potential to improve cancer treatment for colorectal cancer and melanoma by using nanotechnology to deliver chemotherapy in a way that makes it more effective against aggressive tumors.
A novel approach to treating children diagnosed with autism spectrum disorder could help them navigate their world by teaching them to turn their symptoms into strengths.
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that they received approval from the European Commission to proceed with Teva's acquisition of Barr.
The study evaluated the co-occurrence of cancers in patients with central nervous system disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorders, Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia.
Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids.
› Verified 5 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508266347 PECOS PAC ID: 8527972546 Enrollment ID: O20151201002613 |
News Archive
University of Arizona Health Sciences researchers recently completed a study that has the potential to improve cancer treatment for colorectal cancer and melanoma by using nanotechnology to deliver chemotherapy in a way that makes it more effective against aggressive tumors.
A novel approach to treating children diagnosed with autism spectrum disorder could help them navigate their world by teaching them to turn their symptoms into strengths.
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that they received approval from the European Commission to proceed with Teva's acquisition of Barr.
The study evaluated the co-occurrence of cancers in patients with central nervous system disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorders, Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia.
Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emily Ann Dimango, MD 630 W 168th St # 4, Vc 12th Floor, Suite 208, New York, NY 10032-3725 Ph: () - | Dr Emily Ann Dimango, MD 622 W 168th St, New York, NY 10032-3720 Ph: (212) 305-0631 |
News Archive
University of Arizona Health Sciences researchers recently completed a study that has the potential to improve cancer treatment for colorectal cancer and melanoma by using nanotechnology to deliver chemotherapy in a way that makes it more effective against aggressive tumors.
A novel approach to treating children diagnosed with autism spectrum disorder could help them navigate their world by teaching them to turn their symptoms into strengths.
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that they received approval from the European Commission to proceed with Teva's acquisition of Barr.
The study evaluated the co-occurrence of cancers in patients with central nervous system disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorders, Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia.
Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids.
› Verified 5 days ago
Dr. Ravishankar Ramaswamy, MD, MS Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1440 Madison Avenue, New York, NY 10029 Phone: 212-659-8552 Fax: 212-860-9737 | |
Dr. Pietro Alessandro Ambrogio Canetta, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, Ph4-124, New York, NY 10032 Phone: 212-305-5020 Fax: 212-305-6692 | |
Dr. Rakhshan Mahmood Chida, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 327 E 17th St, New York, NY 10003 Phone: 212-420-5690 | |
Charles D Resor, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, New York, NY 10032 Phone: 212-305-2913 | |
Dr. Jacqueline Yuey Lonier, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1150 Saint Nicholas Ave, New York, NY 10032 Phone: 212-851-5494 | |
Dr. Sharon Uralil, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 550 1st Ave, New York, NY 10016 Phone: 212-263-3293 | |
Diana Kantor, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 775 9th Ave, New York, NY 10019 Phone: 212-586-1550 |